A Phase I Study to Evaluate the Safety and Dosimetry of 68Ga-labelled OncoFAP Derivatives in Patients with Solid Tumors
Latest Information Update: 19 Nov 2024
At a glance
- Drugs OncoFAP 68Ga (Primary)
- Indications Adenocarcinoma; Breast cancer; Colorectal cancer; Oesophageal cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Diagnostic use
- Acronyms FAPrimo
- Sponsors Philogen
Most Recent Events
- 15 Nov 2024 Status changed from recruiting to completed.
- 05 Apr 2024 Planned End Date changed from 1 Jan 2024 to 1 Oct 2024.
- 05 Apr 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Oct 2024.